Moody's: Pfizer unchanged

Moody's Investors Service commented that the recently completed strategic review of Pfizer Inc. does not have any immediate impact on Pfizer's A1/prime-1 ratings or its stable outlook.

The agency said it views the decision to explore strategic alternatives for the animal health and nutrition businesses as credit negative, but not enough to affect Pfizer's rating currently.

While divesting the established products and consumer products units may have generated significant proceeds, retaining these businesses helps maintain Pfizer's current level of geographic and product diversity, Moody's said, as well as the steady cash flow generated by these products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.